PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies


Tekesin K., Akar E., Gunes M. E. , Bayrak S., ÖZTÜRK T. , Altinay S., et al.

JOURNAL OF BUON, cilt.24, ss.1920-1926, 2019 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 24 Konu: 5
  • Basım Tarihi: 2019
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayısı: ss.1920-1926

Özet

Purpose: The purpose of this study was to retrospectively investigate the response to trastuzumab in breast cancer patients in terms of the potential roles of several oncogenic pathways (phosphatase and tensin homolog (PTEN) and phosphatidylinositol 3-kinase (PI3K)) in relation to HER2 status.